The EU approval decision for mavorixafor in WHIM syndrome (expected Q2 2026) is a near-term catalyst. While the licensing revenue inflates top-line growth, the core business remains pre-commercial outside U.S. product sales. Monitor 4WARD trial enrollment progress and any updates on commercial expansion in Europe.
Price Chart
Executive Summary
X4 Pharmaceuticals reported Q4 and full-year 2025 financial results with $35.1M in total revenue, driven by a $28.6M licensing deal and $6.5M in product sales. The company posted a net loss of $79.2M but extended its cash runway to 2028. A positive CHMP opinion for mavorixafor in WHIM syndrome in the EU signals potential near-term regulatory approval, while the pivotal 4WARD trial in chronic neutropenia remains on track for enrollment completion in Q3 2026.
Key Financial Metrics
Key Facts
- Net product sales of $6.5M and license/other revenue of $28.6M for full-year 2025
- Operating loss of $86.9M and net loss of $79.2M for 2025
- Cash, cash equivalents, and short-term investments totaled $253.0M as of Dec 31, 2025
- CHMP issued positive opinion recommending EU marketing authorization for mavorixafor in WHIM syndrome
- 4WARD Phase 3 trial enrollment on track for completion in Q3 2026
- Weighted average shares outstanding increased from 6.7M in 2024 to 42.3M in 2025 due to financings
Financial Impact
Revenue surged to $35.1M in 2025 from $2.6M in 2024, primarily due to a $28.6M one-time licensing payment. However, the company remains deeply unprofitable with an $86.9M operating loss. Cash position improved to $253M, funding operations through 2028.
Risk Factors
- Regulatory risk: Final European Commission decision on mavorixafor for WHIM syndrome is not guaranteed
- Clinical risk: 4WARD trial could face delays or fail to meet endpoints
- Dilution risk: Significant share count increase from 6.7M to 42.3M reflects recent equity financings, which may pressure stock price
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3257025 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 8, 2026 18d ago | 8-K | $2.91 | awaiting T+20 | — | $3.25 (+11.68%) |
Oct 7, 2026 19d ago | SC 13G/A | $2.81 | awaiting T+20 | — | $3.25 (+15.66%) |
Oct 1, 2026 25d ago | 144 | $2.83 | awaiting T+20 | — | $3.25 (+14.84%) |
Sep 21, 2026 5w ago | SC 13G | $3.43 $3.02 | ▼ −11.95% | ▼ −11.39% | $3.25 (−5.25%) |
Sep 8, 2026 6w ago | 8-K | $3.51 $2.77 | ▼ −20.97% | ▼ −22.68% | $3.25 (−7.28%) |
Aug 13, 2026 10w ago | Insider Cluster | $4.22 $3.62 | ▼ −14.22% | ▼ −12.23% | $3.25 (−22.99%) |
Aug 13, 2026 10w ago | 144 | $4.29 $3.50 | ▼ −18.41% | ▼ −16.67% | $3.25 (−24.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
Jun 11, 2026 19w ago | Institutional Cluster | $3.88 $3.96 | ▲ +2.06% | ▲ +0.17% | $3.25 (−16.24%) |
May 18, 2026 23w ago | EFFECT | $3.68 $4.04 | ▲ +9.78% | ▲ +8.20% | $3.25 (−11.68%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers